OS Therapies, Inc., a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced that it received a Notice of Allowance from the United ...

New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component for Ebola virus ...

In early January came news that Marquee Brands, which is backed by Neuberger Berman , acquired Laura Ashley, the iconic London-based brand that sells home furnishings and fashion items. The seller was ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel ...

Myris Therapeutics™ emerged from stealth today to announce its strategic focus. Myris, formerly known as BioHybrid Solutions, ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently ...

OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it received a Notice of Allowance from the ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...